Acute coronary syndrome (ACS) comprises of unstable angina (UA), non-ST-segment elevation myocardial infarction (NSTEMI) and ST-segment elevation myocardial infarction (STEMI). ACS is the consequence of a sudden rupture of the coronary artery plaque and the immediate formation of thrombosis around the plaque. The presence of coronary occlusion and thrombus might result in cardiac muscle damage and loss of effective cardiac output, leading to cardiac failure. Anticoagulants, therefore, play an important role in medical management for ACS. This article assesses the role of low molecular weight heparin (LMWH) in ACS based on current available data in clinical trials and clinical practice guidelines from the American College of Cardiology (ACC)/the American Heart Association (AHA) and the American College of Chest Physicians (ACCP) antithrombotic and thrombolytic therapy consensus guidelines. Overall, the use of enoxaparin is generally preferred over other LMWHs when LMWH is indicated, and there is strong support for its role across the continuum of treatment for ACS patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.